GLP-1 Weight Loss Medications Compared: What's Available in Australia
%20Medium.jpeg)
When most people hear about weight loss medication, they picture a single type of treatment. In reality, there are several distinct classes of medication available in Australia, each working through a different biological mechanism. Understanding these differences is not about choosing your own treatment. That is your GP's role. But walking into a consultation with a basic understanding of the landscape means you can have a more informed conversation about what might suit your body, your health profile, and your goals.
The three main classes of weight loss medication currently relevant in Australia are GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and lipase inhibitors. They differ in how they work, how they are administered, what side effects they carry, and who they are best suited for. Your GP considers all of these factors, alongside your blood work, medical history, and lifestyle, when recommending a treatment approach.
What all three classes share is that they work best under medical supervision. None of them are standalone solutions, and none of them replace the fundamentals of nutrition, movement, and ongoing clinical care. They are tools that help your body respond the way it should, prescribed and monitored by a doctor who understands the full picture.
GLP-1 receptor agonists are the most commonly prescribed class of weight loss medication in Australia. They work by mimicking a natural hormone called glucagon-like peptide-1, which your gut produces after eating. This hormone tells your brain you are full, slows the rate at which food leaves your stomach, and helps regulate blood sugar by improving insulin response.
When taken as medication, GLP-1 receptor agonists amplify these natural signals. The result is a sustained reduction in appetite, longer-lasting fullness after meals, and more stable energy levels throughout the day. Patients often describe the experience not as forcing themselves to eat less, but as simply feeling satisfied sooner and thinking about food less often.
Most GLP-1 medications currently available in Australia are administered as a weekly injection using a pre-filled pen device. The injection is subcutaneous, meaning it goes just under the skin, typically in the abdomen, thigh, or upper arm. Most patients find it straightforward after the first one or two doses.
Oral formulations of GLP-1 medications are expected to reach Australia by late 2026 or early 2027. These tablet-based options work through the same biological mechanism but remove the injection requirement entirely, which may make the class accessible to men who would otherwise be hesitant to start treatment.
Clinical trials published in the New England Journal of Medicine have shown average weight reductions of 15 to 22 per cent of body weight over 68 weeks with GLP-1 receptor agonists combined with lifestyle changes. Side effects are most common during the titration phase and typically settle within the first four to six weeks. Nausea, the most frequently reported, is managed by starting at a low dose and increasing gradually under your GP's guidance.
GLP-1 receptor agonists are generally recommended for adults with a BMI of 30 or above, or 27 and above with a weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnoea. PBS subsidies that began in 2026 have made this class significantly more affordable for patients who meet the initial eligibility criteria.
For a deeper look at how GLP-1 medications work, eligibility, costs, and what to expect during treatment, see our comprehensive guide: GLP-1 Weight Loss Medications in Australia: What You Need to Know.
A newer class of weight loss medication targets two hormones instead of one. Dual GIP/GLP-1 receptor agonists activate both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone produced in the gut that plays a role in insulin secretion, fat metabolism, and appetite regulation.
By targeting both pathways simultaneously, dual agonists may produce a stronger metabolic response than GLP-1 medications alone. Clinical trials have shown weight reductions of up to 22.5 per cent of body weight over 72 weeks, with some patients achieving even greater results. These trials also demonstrated significant improvements in blood sugar control, making dual agonists particularly relevant for patients with type 2 diabetes or insulin resistance alongside obesity.
This class is newer to the Australian market and not yet as widely prescribed as single-action GLP-1 medications. Availability and PBS subsidy status may differ from established GLP-1 options. Your GP can advise on whether a dual agonist is available, appropriate for your clinical profile, and how it compares to other options in your specific situation.
The side effect profile is broadly similar to single-action GLP-1 medications. Nausea, constipation, and reduced appetite are the most commonly reported effects during the titration phase. As with GLP-1 receptor agonists, these typically settle within the first few weeks as your body adjusts to each dose increase.
Dual agonists represent an important development in weight management medicine, but they are not automatically better for every patient. The decision between a single-action and dual-action medication depends on your individual health profile, metabolic markers, treatment goals, and how your body responds. This is precisely the kind of nuanced clinical judgment that a GP who knows your full health history is best positioned to make.
Lipase inhibitors represent an older class of weight loss medication that works through an entirely different mechanism. Rather than acting on appetite signals in the brain, they work in the digestive tract by blocking an enzyme called lipase, which is responsible for breaking down dietary fat. When lipase is inhibited, a portion of the fat you eat passes through your body unabsorbed, reducing overall caloric intake.
This class has been available in Australia for longer than GLP-1 medications and was, for many years, the primary pharmacological option for weight management. Clinical evidence shows modest weight loss results compared to newer medication classes, typically in the range of 5 to 10 per cent of body weight over 12 months when combined with a reduced-fat diet.
The side effect profile is distinctive and worth understanding. Because unabsorbed fat passes through the digestive system, gastrointestinal effects are common. These can include oily or fatty stools, increased bowel movements, flatulence, and in some cases, faecal urgency. These effects are directly related to fat intake, meaning they can be managed by following a lower-fat diet, which is part of the clinical guidance your GP provides alongside the prescription.
Lipase inhibitors may be clinically appropriate for patients who are not candidates for GLP-1 medications due to contraindications, personal preference, or other medical considerations. They may also be considered as part of a combined approach in certain clinical scenarios.
It is worth noting that lipase inhibitors do not address the appetite and satiety mechanisms that GLP-1 medications target. For many patients, particularly those whose weight gain is driven by persistent hunger signals or metabolic dysfunction, GLP-1 receptor agonists may offer a more effective approach. Your GP can help you understand which mechanism is most relevant to your individual situation.
Choosing a weight loss medication is a clinical decision, not a consumer one. Your GP does not simply match you to whatever medication is newest or most popular. They assess your individual health profile and recommend the approach most likely to be safe, effective, and sustainable for your specific situation.
The assessment starts with your baseline health data. Your BMI, waist circumference, blood pressure, and blood work results (fasting glucose, HbA1c, lipid profile, liver and kidney function, thyroid hormones) all feed into the clinical picture. A man with insulin resistance and a BMI of 34 has a different treatment profile from a man with normal metabolic markers and a BMI of 31. The medication that suits one may not suit the other.
Your GP also considers your medication history. If you are taking other medications, potential interactions need to be evaluated. Certain pre-existing conditions, such as a personal or family history of pancreatitis, medullary thyroid carcinoma, or severe gastrointestinal disease, may rule out specific medication classes or require additional monitoring.
Lifestyle factors matter too. Your eating patterns, activity levels, work schedule, stress levels, and mental health all influence which treatment approach is most likely to succeed. A medication that requires weekly injections may not suit someone with a needle phobia, just as a medication that demands strict dietary fat reduction may not suit someone whose eating patterns are driven by appetite rather than fat intake.
This is where the difference between a subscription model and a GP-led approach becomes clear. A subscription service may offer one medication class delivered monthly with minimal clinical oversight. A GP who knows your full health history can match the treatment to you, adjust the plan as circumstances change, and monitor for complications that a remote subscription model is not structured to catch.
At Abby Health, that continuity is built into the model. Our care network connects you with a GP who stays with you across appointments, tracking your progress, adjusting your treatment, and making decisions based on your full health story. Consultations can be bulk billed for eligible patients, which means the clinical relationship that leads to better outcomes does not come with a premium price tag.
The purpose of understanding these medication classes is not to arrive at your GP appointment with a prescription in mind. It is to walk in with enough context to have a real conversation about your options.
Your doctor is the expert. They have access to your blood work, your health history, and the clinical training to interpret what those numbers mean for your individual situation. What you bring to the conversation is equally valuable: your experience, your goals, what you have already tried, and what matters to you about how treatment fits into your life.
The best outcomes happen when both sides of that conversation are informed. A GP who listens carefully and a patient who asks good questions will almost always land on a better treatment plan than either could reach alone.
If you want to go deeper on any of the topics covered here, the other articles in this series may help. Our cornerstone guide, GLP-1 Weight Loss Medications in Australia: What You Need to Know, covers the most commonly prescribed class in comprehensive detail. What Is Medically Supervised Weight Loss? explains the full clinical pathway from first appointment to long-term management. And Weight Loss Medication in Australia: What's Changing in 2026 covers the latest PBS subsidies and new formulations on the horizon.
The first step is a conversation with a GP who will take the time to listen, assess, and guide you toward the approach that fits your body and your life. You deserve that level of care.
Editorial Standards
Notice something that doesn’t look right? Let us know at support@abbyhealth.app
Authors
